Goal of this study

To treat Alzheimer’s disease.


Alzheimer’s disease is a brain disease that gradually destroys memory and thinking skills. This study will investigate the efficacy of a drug named Azeliragon in slowing down disease progression in patients with early Alzheimer’s disease (also known as mild dementia). This study will also investigate the safety of Azeliragon. Azeliragon will be given to the patient through the mouth once daily for 18 months.

Who can participate in this study?

Patients who have been diagnosed with mild Alzheimer’s disease (also known as mild dementia) and who are 50 years and older may be eligible to participate in this study. This study accepts both men and women and does not accept healthy volunteers.

Important: Additional eligibility criteria apply and the patient’s record will be verified by the study doctor (with the patient’s approval) to confirm eligibility.

Clinicaltrials.gov identifier: NCT02080364

Contact Information

To know if you're eligible to participate in this trial, please fill-up the form below and we will contact you shortly.